三阴性乳腺癌
癌症研究
基因敲除
下调和上调
癌基因
生物
癌症
转移
乳腺癌
细胞凋亡
细胞周期
遗传学
生物化学
基因
作者
Yin‐Ling Zhang,Min‐Ying Huang,Shao‐Ying Yang,Jianhui Cai,Qian Zhao,Fang-Lin Zhang,Xin Hu,Zhimin Shao,Li Liao,A‐Yong Cao,Da‐Qiang Li
标识
DOI:10.1002/advs.202500421
摘要
Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer due to its aggressive clinical features and the lack of effective targeted therapeutics. Mitochondrial metabolism is intimately linked to TNBC progression and therapeutic resistance and is an attractive therapeutic target for TNBC. Here, it is first reported that human transmembrane protein 65 (TMEM65), a poorly characterized mitochondrial inner-membrane protein-encoding gene in human cancer, acts as a novel oncogene in TNBC to promote tumor growth, metastasis, and cisplatin resistance both in vivo and in vitro. Transcription factor MYC and DNA demethylase ten-eleven translocation 3 (TET3) coordinately upregulate TMEM65 in TNBC, and its upregulation is associated with poor patient survival. Moreover, pharmacological inhibition or knockdown of MYC and TET3 attenuates TMEM65-driven TNBC progression. Mechanistic investigations reveal that TMEM65 enhances mitochondrial oxidative phosphorylation and its byproduct reactive oxygen species (ROS) production. Increased ROS induces the expression of hypoxia-inducible factor 1α (HIF1α), which in turn transcriptionally activates serpin family B member 3 (SERPINB3) to enhance TNBC stemness, thus leading to TNBC progression and cisplatin resistance. Collectively, these findings identify TMEM65 as a vital oncogene of TNBC, unveil its regulatory mechanisms, and shed light on its potential role in TNBC therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI